Paper36934257
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
Amaro A and 23 others. J Exp Clin Cancer Res, 2023. Cited by 31 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Papers, record 36934257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36934257
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Myeloid-Derived Suppressor Cells | Major topic |
| Melanoma | Major topic |
| Animals | |
| Mice | |
| CTLA-4 Antigen | |
| T-Lymphocytes, Regulatory | |
| Killer Cells, Natural | |
| Tumor Microenvironment | |
| Azacitidine |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 21073 | Associazione Italiana per la Ricerca sul Cancro | PubMed | ||
| 21073 | Associazione Italiana per la Ricerca sul Cancro | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | Derived from the trial | Yes |
Source ClinicalTrials.gov
References83
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21436444 | Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. | Science | 2011 | https://conductscience.org/library/papers/21436444 | PubMed |
| 2 | 19118225 | Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. | Eur Respir J | 2009 | https://conductscience.org/library/papers/19118225 | PubMed |
| 3 | 33767177 | Targeting macrophages in cancer immunotherapy. | Signal Transduct Target Ther | 2021 | https://conductscience.org/library/papers/33767177 | PubMed |
| 4 | 31897157 | Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome. | Oncol Lett | 2020 | https://conductscience.org/library/papers/31897157 | PubMed |
| 5 | 26027431 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26027431 | PubMed |
| 6 | 17096021 | TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. | J Invest Dermatol | 2007 | https://conductscience.org/library/papers/17096021 | PubMed |
| 7 | 28272106 | M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma. | Melanoma Res | 2017 | https://conductscience.org/library/papers/28272106 | PubMed |
| 8 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 9 | 22368280 | Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection. | J Leukoc Biol | 2012 | https://conductscience.org/library/papers/22368280 | PubMed |
| 10 | 35550530 | CD39 - A bright target for cancer immunotherapy. | Biomed Pharmacother | 2022 | https://conductscience.org/library/papers/35550530 | PubMed |
| 11 | 31548600 | The emerging role of epigenetic therapeutics in immuno-oncology. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31548600 | PubMed |
| 12 | 11849319 | Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. | Immunology | 2002 | https://conductscience.org/library/papers/11849319 | PubMed |
| 13 | 24478339 | Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. | Bioinformatics | 2014 | https://conductscience.org/library/papers/24478339 | PubMed |
| 14 | 34795289 | Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo. | Nat Commun | 2021 | https://conductscience.org/library/papers/34795289 | PubMed |
| 15 | 9521319 | Dendritic cells and the control of immunity. | Nature | 1998 | https://conductscience.org/library/papers/9521319 | PubMed |
| 16 | 15611321 | PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. | Int Immunol | 2005 | https://conductscience.org/library/papers/15611321 | PubMed |
| 17 | 34265363 | Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. | Life Sci | 2021 | https://conductscience.org/library/papers/34265363 | PubMed |
| 18 | 25403716 | Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. | Cancer Immunol Res | 2015 | https://conductscience.org/library/papers/25403716 | PubMed |
| 19 | 28447602 | Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. | Nat Commun | 2017 | https://conductscience.org/library/papers/28447602 | PubMed |
| 20 | 34066538 | Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28- T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34066538 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649503 | Current and future therapies for triple-negative breast cancer. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42649503 | PubMed |
| 42500571 | Epigenetic Modulators and Immunotherapy in Malignant Melanoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42500571 | PubMed |
| 42439659 | Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence. | Cells | 2026 | https://conductscience.org/library/papers/42439659 | PubMed |
| 42435177 | Epigenetic Targeting in Myeloid Malignancies. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435177 | PubMed |
| 42426902 | Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42426902 | PubMed |
| 42194057 | Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194057 | PubMed |
| 41930165 | Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930165 | PubMed |
| 41797904 | Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. | iScience | 2026 | https://conductscience.org/library/papers/41797904 | PubMed |
| 41684028 | A New Complexity Layer: DNA Methylation and the Predictive Impact of Epigenetic Tests. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41684028 | PubMed |
| 41550427 | The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer. | Cancer Heterog Plast | 2025 | https://conductscience.org/library/papers/41550427 | PubMed |
| 41541220 | Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/41541220 | PubMed |
| 41294748 | Cancer and Aging Biomarkers: Classification, Early Detection Technologies and Emerging Research Trends. | Biosensors (Basel) | 2025 | https://conductscience.org/library/papers/41294748 | PubMed |
| 40787072 | The Systematic Comparison of Enhancer of Zeste Homolog-2-, Bromodomain-containing Proteins-, Histone Deacetylase-, and DNA-methyltransferase 1-inhibitors in a Syngeneic Murine Model of Melanoma Reveals Differential Anti-tumoral and Immunomodulatory Activities. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40787072 | PubMed |
| 40682094 | Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40682094 | PubMed |
| 40641934 | The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies. | Front Oncol | 2025 | https://conductscience.org/library/papers/40641934 | PubMed |
| 40325471 | Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective. | Clin Epigenetics | 2025 | https://conductscience.org/library/papers/40325471 | PubMed |
| 40317004 | Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40317004 | PubMed |
| 40038722 | The epigenetic hallmarks of immune cells in cancer. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40038722 | PubMed |
| 40012016 | Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors. | Biomark Res | 2025 | https://conductscience.org/library/papers/40012016 | PubMed |
| 39592582 | Epigenetics-targeted drugs: current paradigms and future challenges. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39592582 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CDA | 978 | PubTator's text mining | https://conductscience.org/library/genes/978 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| DNMT1 | 1786 | PubTator's text mining | https://conductscience.org/library/genes/1786 | NCBI Gene |
| ICAM1 | 3383 | PubTator's text mining | https://conductscience.org/library/genes/3383 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| IPILIMUMAB | CHEMBL1789844 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1789844 | ChEMBL |
| GUADECITABINE | CHEMBL3544916 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3544916 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36934257
GET https://conductscience.org/api/papers/v1/36934257/authors?page=2